The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Canakinumab Treatment Effective for Familial Mediterranean Fever

Canakinumab Treatment Effective for Familial Mediterranean Fever

April 23, 2018 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Familial Mediterranean fever (FMF) is, perhaps, the oldest and most common hereditary autoinflammatory disease. The autosomal, recessive, monogenic disease primarily affects Turks, Armenians, non-Ashkenazi Jews and Arabs. Colchicine is the first-line treatment for FMF because, for most patients, it prevents both inflammatory attacks and the development of amyloidosis.

You Might Also Like
  • How to Recognize, Diagnose Periodic Fever Syndromes in Adults
  • Canakinumab Reduces Risk for Gout Flares, But Not Serum Uric Acid Levels
  • Long-Term Canakinumab Treatment Has Favorable Effect on Systemic Features & Joint Health for sJIA
Also By This Author
  • Chronic Fatigue Syndrome: Why Myalgic Encephalomyelitis Is the Preferred Term and More

Unfortunately, approximately 5–10% of patients with FMF do not respond well to colchicine. Consequently, anti-interleukin (IL) 1 drugs, such as anakinra, rilonacept and canakinumab, have emerged as treatment options for colchicine-resistant and/or intolerant FMF. This choice is supported by a retrospective study that demonstrated that canakinumab is able to achieve rapid and sustained remission in patients with colchicine-resistant FMF.1 Moreover, a systemic review found 76.5% of patients treated with anakinra and 67.5% of patients treated with canakinumab experienced a complete response to therapy without a single attack during treatment.2 For patients with established type amyloid A amyloidosis, anti-IL-1 treatment can even reverse proteinuria. Unfortunately, canakinumab, a human immunoglobulin (Ig) G antibody directed against IL-1 beta, has not been shown to prevent the development of amyloidosis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Some patients with FMF require renal transplant and must then be treated with immunosuppressive drugs. These immunosuppressive drugs can interact with colchicine and increase the incidence of side effects, such as diarrhea and myopathy, in transplant recipients. Although the literature includes descriptions of anakinra use for patients with renal transplants, no published reports of canakinumab use for these patients exist. Now, Tolga Yildirim, MD, PhD, associate professor of nephrology at Hacettepe University in Turkey, and colleagues present a case series that suggests that canakinumab is a useful first-line option for the treatment of renal transplant recipients with FMF. Their paper, published online Feb. 14 in the Journal of Nephrology, indicates that canakinumab has equal efficacy and better tolerability than anakinra in these patients.

The authors report their three patients achieved a complete clinical response, including the elimination of attacks and normalization of serum C-reactive protein (CRP) levels. These benefits were achieved without significant side effects. Their series included a 61-year-old Turkish woman who had been diagnosed with FMF at age 26, a 57-year-old Turkish woman with end stage renal disease (ESRD) secondary to FMF/amyloidosis and a 46-year-old Turkish woman with ESRD secondary to FMF/amyloidosis. Patient 1 received canakinumab treatment for six months, and her renal function remained stable with serum creatinine between 0.8 and 1.0 mg/dL. Patient 2 received canakinumab treatment for three months, and although she developed chronic pyelonephritis, her serum creatinine remained stable at approximately 1.4 mg/dL. Patient 3 received 12 months of treatment with canakinumab, and her creatinine level remained stable at 1.3 mg/dL.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: canakinumab, Familial Mediterranean fever, kidney transplant, Renal, transplantation

You Might Also Like:
  • How to Recognize, Diagnose Periodic Fever Syndromes in Adults
  • Canakinumab Reduces Risk for Gout Flares, But Not Serum Uric Acid Levels
  • Long-Term Canakinumab Treatment Has Favorable Effect on Systemic Features & Joint Health for sJIA
  • Diagnosis, Treatment for Patient with Psoriasis, Fever, Bloating, and Rash

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.